Understanding wtATTR-CM heart disease (TRACE 1)
Part of Heart & circulation clinical trials.
This study aims to better understand a type of heart disease called wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM). It will compare people with this condition to a control group without known heart disease to identify key features.
Summary written for real people, not researchers, by Clin2.
Who can take part
- For the wtATTR-CM group: You must be over 18 and have a confirmed diagnosis of wtATTR-CM through a heart biopsy or a special scan (DPD scintigraphy) with specific findings.
- You cannot have other amyloid-related diseases like AL amyloidosis, myelomatosis, or Waldenström macroglobulinemia.
- For the control group: You must be over 18 and have no known significant heart problems (like heart failure, atrial fibrillation, or a pacemaker).
- For controls: You must have no signs or symptoms that might suggest cardiac amyloidosis, such as thickened heart walls, specific changes on your echocardiogram, or nerve issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses heart scans to see how the drug acoramidis affects heart structure and function in people with a specific type of heart disease called ATTR cardiomyopathy. It may help doctors understand if the treatment is working.
This study tests a new medication called coramitug to see if it can reduce abnormal protein deposits in the heart. You will have special PET/CT scans to measure how the drug affects these deposits.
This study uses retinal imaging (pictures of the back of the eye) and OCT scans to look for signs of a specific heart condition called transthyretin amyloid cardiomyopathy (ATTR-CM). It may help doctors find this condition with an eye exam instead of more invasive tests.
This study follows patients with ATTR amyloidosis over time to understand how the disease affects them. It does not test a new treatment—instead, it asks you to fill out questionnaires about your health and symptoms to help doctors learn more about the condition.
This study looks at people who carry certain TTR gene variants, which can cause a specific type of heart amyloid buildup. It also includes people with symptoms, to understand how the condition develops and how it may be monitored.
This registry collects information from people with ATTR-CM, a condition where abnormal protein builds up in the heart. By joining, you help researchers learn more about the disease and improve future care.
Hear when a new Transthyretin Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.